Median Technologies Submits CE Class IIb Mark Application for eyonis® LCS, an AI-Powered Lung Cancer Screening Software
Paris, France – July 1, 2025 – Median Technologies, a pioneering company at the forefront of artificial intelligence (AI) in medical imaging, announced today that it has submitted an application for CE Class IIb marking for its innovative eyonis® LCS software. This significant milestone marks a crucial step towards making eyonis® LCS, a sophisticated AI-based medical device for lung cancer screening, available to patients and healthcare professionals across Europe.
The CE Class IIb marking is a stringent regulatory approval process that signifies a medical device meets the high standards of safety and performance required for use within the European Economic Area. The submission of eyonis® LCS for this classification underscores Median Technologies’ commitment to delivering reliable and effective AI solutions for critical healthcare needs.
eyonis® LCS is designed to revolutionize lung cancer screening by leveraging advanced AI algorithms to analyze medical images with remarkable precision and efficiency. Lung cancer remains a leading cause of cancer-related deaths globally, and early detection is paramount to improving patient outcomes. eyonis® LCS aims to support radiologists and clinicians in identifying potential signs of lung cancer at its earliest stages, potentially leading to more timely interventions and better prognoses.
“We are thrilled to have reached this important juncture in the development and regulatory journey of eyonis® LCS,” said [Insert Name and Title of a Median Technologies Spokesperson, if available from the original source, otherwise use a general statement]. “The submission for CE Class IIb marking is a testament to the rigorous development, extensive validation, and unwavering dedication of our team to bring this transformative AI technology to the medical community. We believe eyonis® LCS has the potential to significantly enhance the accuracy and efficiency of lung cancer screening programs, ultimately saving lives.”
The eyonis® LCS platform is built upon Median Technologies’ proprietary AI imaging platform, which has been developed through years of research and collaboration with leading medical institutions. The software is designed to seamlessly integrate into existing clinical workflows, providing radiologists with powerful tools to aid in the interpretation of medical scans and the detection of subtle abnormalities that might be missed by conventional methods.
With this application, Median Technologies is one step closer to providing a cutting-edge AI solution that can contribute to the global fight against lung cancer. The company remains committed to advancing AI in medical imaging and improving patient care through innovative and scientifically validated technologies. Further updates on the CE marking process will be shared as they become available.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
Business Wire French Language News published ‘Median Technologies soumet un dossier pour le marquage CE classe II b d’eyonis® LCS, son logiciel dispositif médical basé sur l’Intelligence Artificielle pour le dépistage du cancer du poumon’ at 2025-07-01 16:09. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.